Navigation Links
Suven Life Sciences Presenting Pre-clinical data of their,NCE’s SUVN-502 and SUVN-507at International Brain Research,Organization (IBRO) 2007 World Congress of Neuroscience

HYDERABAD, India, July 5th, 2007 – Several data presentations from Suven’s portfolio of investigational neuroscience compounds will be presented at International Brain Research Organisation (IBRO) 2007 World Congress of Neuroscience to be held at Melbourne, Australia during July 12-17, 2007.

Scientists from Suven Discovery Research will be presenting new data for 4 promising areas of neuroscience viz. Alzheimer’s, Schizophrenia, Parkinson and Obesity diseases. These areas present significant unmet medical need for which current treatment options are insufficient. Suven has a number of programs in each of these areas, focusing on novel approaches that may lead to the development of new therapies for patients.
Suven is presenting the data on their leading preclinical candidates SUVN-502 and SUVN-507 at IBRO 2007 world congress of Neuroscience .

Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven’s discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven’s CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, Schizophrenia, Depression, Cognitive disorders and Neurodegeneration.

Suven Life Sciences, a Hyderabad based Life Sciences Company, pioneer in Contract Research And Manufacturing Services (CRAMS) since 1995 in its endeavor to become collaborative research partner (CRP) for global life science companies has embarked on new business model “Drug Discovery and Development Support Services” (DDDSS) with the onset of Intellectual Property Regime in India since January 2005.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven
'"/>




Page: 1 2

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
4. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
7. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
10. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
11. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
Post Your Comments:
(Date:7/29/2014)... 29, 2014 Cynosure, Inc. (Nasdaq: ... and light-based aesthetic treatment systems for high-volume applications, today ... 30, 2014. Second-quarter 2014 financial results incorporate the acquisition ... 24, 2013. Second-Quarter 2014 Financial ... to $72.6 million , Non-GAAP net income of ...
(Date:7/29/2014)...  The Healthcare Analytics Summit 2014 (HAS ... Salt Lake City , Sept. 24-25 has added ... organizations in the U.S. and beyond.  HAS ,14, powered ... devoted to providing immersive learning experiences on the ... accountable care initiatives and population health managemen t ...
(Date:7/29/2014)... , July 29, 2014 Apex Medical Corporation ... and Pressure Area Care sectors, announces that it is appealing ... in Germany that found ... Apex notes that it has initiated invalidity challenges against various ... efforts in counterattacking against trivial and junk patents. ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5Apex Continues Fighting Against Patents to Free Up Competition 2
... initiate Phase 1 trial of AKIi-5 as the first ... ... Aug. 2 Quark Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company ... today the,presentation of positive results from preclinical efficacy studies ...
... PHILADELPHIA, Aug. 3 GlaxoSmithKline (NYSE:,GSK), one of ... has placed another order to purchase bulk H5N1 ... The company also announced the,start of the first ... pre-pandemic influenza program. HHS Order The ...
Cached Medicine Technology:Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 2Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 3Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 4GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 2GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 3GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 4
(Date:7/29/2014)... Roanoke, Virginia (PRWEB) July 29, 2014 ... a featured lecturer at the Florida Chiropractic Association (FCA) ... and Their Effects on the Kinetic Chain Changes on ... Florida. Greenawalt’s talk is focusing on the positive impact ... on conditions such as low back pain, plantar fasciitis, ...
(Date:7/29/2014)... 29, 2014 Healthcare staffing agency ... Nurses of Tomorrow Scholarship Competition winners:, ... NV ,     Racheal D., Freshman, Cerritos College ... Houston Community College in Houston, TX ... Medical Solutions hosts the Nurses of Tomorrow Scholarship ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 PharmaSphere: ... Biosimilars Market report is an essential source of ... Using detailed company data, financial analysis, corporate strategy, ... of the current and future growth drivers of ... regulatory frameworks under which biosimilars are currently reviewed ...
(Date:7/29/2014)... 29, 2014 1WorldSync announces B. ... healthcare suppliers will utilize the Global Data Synchronization ... network to share product information with the U.S. ... partners across their global supply chain. Holger Clobes, ... B. Braun: "B. Braun serves customers in 61 ...
(Date:7/29/2014)... Catalent Pharma Solutions, the global leader ... for pharmaceutical, biologic, and consumer health products, today ... US Platform Leader of Pharmaceutical Softgels, will present ... Formulations using Soft Capsule Delivery Systems” at the ... of Drug Delivery Systems (30-31 July 2014, Tokyo, ...
Breaking Medicine News(10 mins):Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2
... pre-packed Camembert to shrink-wrapped meat loaf choosing the ... industry. Companies need to protect food products from oxygen, ... fresh for as long as possible. Transparent multilayer films, ... used to protect food from contamination. To minimize the ...
... Tuning in to tune out may be just what,s ... at the Duke Cancer Institute. The Duke team found ... pain and anxiety of the often uncomfortable procedure. The ... points to a simple and inexpensive way to help an ...
... This release is available in Spanish . ... gather and characterise in detail 110 cases of cardiac rupture ... Hospital de Cruces, near Bilbao. It is one of the ... most serious complication of acute myocardial infarction; it is not ...
... new study by NYU Langone Medical Center researchers identified ... of fat and cholesterol that hardens into plaque and ... Immunology on January 8, 2012, explains why cholesterol-laden, ... plaques. "We have discovered that macrophages that accumulate ...
... , SUNDAY, Jan. 8 (HealthDay News) -- People ... genes as those in the general population, but they may ... so long, researchers report. The team of U.S. scientists ... with only one per 5 million people in developed nations. ...
... at the Translational Genomics Research Institute (TGen) have begun ... to lung cancer in never-smokers a first step ... starting point. We certainly have a lot of pathways ... very interested in confirming and looking at in larger ...
Cached Medicine News:Health News:Film coatings made from whey 2Health News:Film coatings made from whey 3Health News:Headphone music eases anxiety during prostate biopsies 2Health News:Keys for detecting cardiac rupture 2Health News:Keys for detecting cardiac rupture 3Health News:Researchers discover new culprit in atherosclerosis 2Health News:Why Some People Live to 110 2Health News:TGen researchers map potential genetic origins, pathways of lung cancer in nonsmokers 2
... is an excellent choice to treat DeQuervain's ... joint, basal joint arthritis, advanced carpal tunnel ... thumb and wrist. Distal palmar crease ... and full finger dexterity. Constructed from ...
... Wrist Flex is a custom wrist orthotic designed to ... to the patient's maximum range-of-motion. , ,Indications: , ... TFCC tear-triangular fibrocartilage complex , Coles fracture ... , Partial tendon rupture , ORIF ...
The Contoured Wrist/Forearm Support provides comfort for post-surgical immobilization, post-fracture casting, and wrist sprains and strains....
Design allows for easy-one hand application to provide support and immobilization of the wrist while preserving finger mobility...
Medicine Products: